Considering the novelty of selectively targeting domain 2 or 3 of VCAM-1 as a strategy for directly combating monocyte recruitment, the tested mAbs represent an intriguing platform for site-specific atherosclerosis nanotherapeutics. Here, VCAM1 is linked to atherosclerosis.